Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Jan 21;27(1):133.
doi: 10.1186/s13063-025-09218-6.

Experiences of conducting effective Patient and Public Involvement and Engagement (PPIE) by the WILL Trial (When to Induce Labour to Limit risk in pregnancy hypertension) management team

Collaborators, Affiliations

Experiences of conducting effective Patient and Public Involvement and Engagement (PPIE) by the WILL Trial (When to Induce Labour to Limit risk in pregnancy hypertension) management team

Katie Kirkham et al. Trials. .

Abstract

Background: Patient and Public Involvement and Engagement (PPIE) is an essential element of any clinical trial, to ensure that the research design and resources are acceptable and the trial produces findings that are relevant to research participants and service-users. The WILL (When to Induce Labour to Limit risk in pregnancy hypertension) Trial Management Team involved a group of patient and public members to develop an infographic, for service-users and -providers, to communicate the risks of chronic and gestational hypertension at term gestational age.

Methods: Based on national resources in the UK for PPIE, including those from the National Institute for Health and Care Research (NIHR) and Health Research Authority, active trial sites (all in the UK) were approached to invite women with pregnancy hypertension to the PPIE group, and advertisements were placed on the Action on Pre-Eclampsia Charity (APEC) and NIHR People in Research websites. PPIE resources were established by the Trial Management Team and virtual meetings with the PPIE members held to co-design and develop the infographic from existing trial materials, using Microsoft Publisher.

Results: Seven diverse PPIE members were involved, six from NIHR People in Research and one from APEC. No members were engaged from active sites. From initial set-up to REC approval of the infographic took 9 months, and a considerable time commitment from the Trial Manager and Senior Research Midwives, to navigate practicalities (e.g. team consensus-building). Four meetings were held and 15 iterations of the infographic were developed with the group. The infographic incorporated requests from PPIE members for a design that was inclusive of all races, cultures, abilities and genders. Discussions with PPIE group members improved our understanding of the acceptability of the trial intervention to some cultures. The Research Ethics Committee (REC) requested revisions to PPIE-approved wording about the risk of stillbirth, from '1 in 1000' to 'small increased risk' prior to issuing approval for use.

Conclusions: More practical support would be useful for researchers seeking to establish PPIE groups, and RECs reviewing resources that are co-produced. Our case study provides a practical, step-by-step account of establishing a PPIE group without a funded co-lead, highlighting strengths such as the diversity of members, the incorporation of cultural perspectives, and the development of inclusive patient-facing materials. These findings add to PPIE practice by offering operational guidance, lessons learned and a summary checklist as an additional resource that can complement existing high-level frameworks.

Trial registration: ISRCTN77258279, registered on 05 December 2018.

Keywords: Engagement; Involvement; Patient; Public; Trial management.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Ethics approval has been obtained (NHS Health Research Authority London Fulham Research Ethics Committee, 18/LO/2033). Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
WILL Hypertension in Pregnancy Infographic V1.0 08Nov2022. Legend: Infographic showing the risks of chronic or gestational hypertension in pregnancy

References

    1. Magee LA, Brown MA, Hall DR, Gupte S, Hennessy A, Karumanchi SA, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022;27:148–69. - DOI - PubMed
    1. Kirkham K, Tohill S, Hutcheon JA, Dorling J, Gkini E, Moakes CA, et al. Will (when to induce labour to limit risk in pregnancy hypertension): protocol for a multicentre randomised trial. Pregnancy Hypertens. 2023;32:35–42. - DOI - PubMed
    1. Magee LA, Kirkham K, Tohill S, Gkini E, Moakes C, Dorling J et al. Determining optimal timing of birth for women with chronic or gestational hypertension at term: the WILL (When to Induce Labour to Limit risk in pregnancy hypertension) randomised trial. PLOS Medicine, in press October 2024. - PMC - PubMed
    1. WILL trial training page for site staff: complications of chronic and gestational hypertension. https://www.birmingham.ac.uk/documents/college-mds/trials/bctu/will/trai.... Accessed 25 Sep 2024.
    1. Hypertension in pregnancy: diagnosis and management. NICE guideline [NG133] Published: 25 June 2019 Last updated: 17 April 2023. https://www.nice.org.uk/guidance/NG133. Accessed 25 Sep 2024.

LinkOut - more resources